We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+32.7%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.21B
AUM Growth
+$566M
Cap. Flow
+$396M
Cap. Flow %
32.65%
Top 10 Hldgs %
61.2%
Holding
106
New
26
Increased
22
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$20.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19M
3
NVS icon
Novartis
NVS
+$17.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.6M
5
NVO
Novo Nordisk
NVO
+$10.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.8M
2
ARQL
Arqule Inc
ARQL
+$20.7M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 6.25%
3 Industrials 0.98%
4 Consumer Discretionary 0.93%
5 Communication Services 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$340M
$8.24M 0.68%
361,888
-298,112
-45% -$4.98M
ARVN icon
27
Arvinas
ARVN
$518M
$8.17M 0.67%
198,781
-6,500
-3% -$190K
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.05M 0.66%
77,000
+3,000
+4% +$336K
PRQR icon
29
ProQR Therapeutics
PRQR
$243M
$7.98M 0.66%
805,000
-110,000
-12% -$857K
AUDC icon
30
AudioCodes
AUDC
$244M
$7.86M 0.65%
306,053
-22,210
-7% -$486K
FISV
31
Fiserv Inc
FISV
$28.8B
$7.78M 0.64%
67,279
– –
XFOR icon
32
X4 Pharmaceuticals
XFOR
$375M
$7.7M 0.63%
24,000
+22,420
+1,419% +$8.04M
SWTX
33
DELISTED
SpringWorks Therapeutics
SWTX
$7.7M 0.63%
200,000
-110,000
-35% -$2.57M
PTLA
34
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$7.57M 0.62%
317,000
+57,000
+22% +$1.57M
ISEE
35
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.45M 0.61%
+868,200
New +$3.1M
STOK icon
36
Stoke Therapeutics
STOK
$1.8B
$7.26M 0.6%
256,380
-90,000
-26% -$2.26M
PANW icon
37
Palo Alto Networks
PANW
$270B
$7.16M 0.59%
185,856
-12,000
-6% -$454K
ZYME icon
38
Zymeworks
ZYME
$1.61B
$7.14M 0.59%
157,000
-13,000
-8% -$472K
DTIL icon
39
Precision BioSciences
DTIL
$180M
$6.86M 0.57%
16,458
+4,291
+35% +$1.35M
AMZN icon
40
Amazon
AMZN
$2.92T
$6.84M 0.56%
74,000
+30,000
+68% +$2.66M
YMAB
41
DELISTED
Y-mAbs Therapeutics
YMAB
$6.67M 0.55%
213,293
+23,293
+12% +$689K
KPTI icon
42
Karyopharm Therapeutics
KPTI
$43.5M
$6.33M 0.52%
+22,000
New +$4.77M
ALDX icon
43
Aldeyra Therapeutics
ALDX
$92.9M
$6.21M 0.51%
1,069,089
– –
GRTX
44
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$6.2M 0.51%
+471,439
New +$5.75M
NERV icon
45
Minerva Neurosciences
NERV
$185M
$6.08M 0.5%
106,875
+11,623
+12% +$513K
ARQL
46
DELISTED
Arqule Inc
ARQL
$5.93M 0.49%
297,227
-1,785,416
-86% -$20.7M
KA
47
DELISTED
Kineta, Inc. Common Stock
KA
$5.78M 0.48%
+18,119
New +$4.07M
HARP
48
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$5.68M 0.47%
38,403
+1,000
+3% +$152K
BLUE
49
DELISTED
bluebird bio
BLUE
$5.66M 0.47%
+4,979
New +$5.41M
FVRR icon
50
Fiverr
FVRR
$321M
$5.49M 0.45%
233,805
+92,450
+65% +$2.04M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sphera Funds Management held 106 positions worth $1.21B, up 87% from $647M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sphera Funds Management deployed $396M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 74% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Arqule Inc, an estimated $20.7M trimmed.

  • Sphera Funds Management's largest Q4 2019 buy was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.
  • Sphera Funds Management added most to Sanofi in Q4 2019, an estimated $20.6M increase.
  • Sphera Funds Management's biggest Q4 2019 reduction was Arqule Inc, cutting an estimated $20.7M.
  • Sphera Funds Management fully exited Celgene Corp in Q4 2019, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 61% of its $1.21B portfolio in Q4 2019.
  • Sphera Funds Management opened 26 new positions and closed 20 in Q4 2019.
  • Sphera Funds Management's portfolio value rose 87% quarter-over-quarter to $1.21B.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.